A Phase 1 interventional study of Sitagliptin phosphate and Comparator: matching placebo in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 147th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 51st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 131st largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 55 in phase 1, and was the 56th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
genitourinary abnormalities or diseases
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to sitagliptin 50 mg
Drug: Sitagliptin phosphate
Participants were randomized to sitagliptin 100 mg
Drug: Sitagliptin phosphate
Participants were randomized to a single dose of sitagliptin 200 mg
Drug: Sitagliptin phosphate
Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
Drug: Comparator: matching placebo
Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
Also known as: MK-0431, Januvia
Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
Number of Participants Who Experienced at Least One Adverse Event
Time frame: Pre-study through 10 to 14 days following administration of study drug
Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin
Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
Time frame: Pre-dose through 72 hours post-dose
Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin
Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
Time frame: Pre-dose through 72 hours post-dose
Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin
Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
Time frame: Pre-dose through 72 hours post-dose
Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin
Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
Time frame: Pre-dose through 72 hours post-dose
Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo
Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose. WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.
Time frame: Pre-dose through 24 hours post-dose
| Milestone | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo |
|---|---|---|---|---|
| Started | 9 | 9 | 8 | 9 |
| Completed | 9 | 9 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| participants | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo |
|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event | 3 | 1 | 1 | 2 |
Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
| nM*hour | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg |
|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin | 3438 (2881 to 4103) | 5869 (4918 to 7003) | 12965 (10749 to 15638) |
Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
| nM | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg |
|---|---|---|---|
| Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin | 366 (288 to 464) | 666 (526 to 845) | 1876 (1458 to 2413) |
Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
| hours | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg |
|---|---|---|---|
| Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin | 3.0 (1.5 to 5.0) | 3.0 (2.0 to 4.5) | 2.5 (1.0 to 3.1) |
Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
| hours | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg |
|---|---|---|---|
| Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin | 12.1 ± 1.7 | 11.2 ± 2.1 | 11.7 ± 1.8 |
Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose. WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.
| Percent inhibition | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo |
|---|---|---|---|---|
| 24-hour WAI of DPP-4 activity | 73.98 (70.59 to 76.99) | 80.53 (77.98 to 82.78) | 87.96 (86.29 to 89.43) | 6.76 (-6.21 to 18.14) |
| DDP-4 activity at 24 hours post-dose | 53.98 (46.74 to 60.24) | 62.78 (56.92 to 67.84) | 75.76 (71.70 to 79.24) | 3.57 (-12.60 to 17.43) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 50 mg | — | 0/9 (0%) | 3/9 (33.3%) |
| Sitagliptin 100 mg | — | 0/9 (0%) | 1/9 (11.1%) |
| Sitagliptin 200 mg | — | 0/8 (0%) | 1/8 (12.5%) |
| Placebo | — | 0/9 (0%) | 2/9 (22.2%) |
| Event | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/9 | 0/9 | 1/8 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 0/9 | 0/8 | 1/9 |
| Abdominal painGastrointestinal disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| Abdominal pain upperGastrointestinal disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| Infusion site painGeneral disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| Infusion site swellingGeneral disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| PyrexiaGeneral disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/9 | 0/9 | 0/8 | 0/9 |
| HeadacheNervous system disorders | 0/9 | 0/9 | 0/8 | 1/9 |
| Age, Continuous(years) | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 13.9 ± 2.52 | 14.3 ± 1.41 | 14.8 ± 1.75 | 14.1 ± 2.26 | 14.3 ± 1.98 |
| Sex: Female, Male(Participants) | Sitagliptin 50 mg | Sitagliptin 100 mg | Sitagliptin 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 6 | 5 | 5 | 8 | 24 |
| Male | 3 | 4 | 3 | 1 | 11 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jul 2008 to primary completion in Dec 2010, 29 months.
Results were first posted in Jan 2012, 1 year 1 month after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 29 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin